Disclosure of the total number of voting rights and the number of shares of the share capital
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has published information on the total number of voting rights and number of shares comprising the share capital on august 23rd 2015, in accordance with the provisions of article 223-16.
Date
Number of shares
Number of voting rights
August 23rd 2015
6,927,334
Theoretical
8,187,326
Exercisable(1)
8,163,991
(1) The total number of voting rights is calculated based on the total shares minus shares without voting rights treasury shares. On august 23rd 2015, 23,335 shares, representing a total of 23,335 voting rights, were registered under the liquidity contract assigned to the brokerage Invest Securities.
Quantum Genomics
Lionel Ségard
Chairman & Chief Executive Officer
01 60 13 76 80
Quantum Genomics
Marc Karako
CFO – Investor Relations
01 60 13 76 84
marc.karako@quantum-genomics.com
ACTUS finance et communication
Jean-Michel Marmillon
Press Relations
01 53 67 36 73
jmmarmillon@actus.fr
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
Information relative au nombre total de droits de vote et d'actions composant le capital :
-
Full and original press release in PDF:
http://www.actusnews.com/documents_communiques/ACTUS-0-41035-QGC_shares-voting-rights_20150824_UK-VF.pdf
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Quelle: Actusnews